Hormonal therapies up-regulate MANF and overcome female susceptibility to immune checkpoint inhibitor myocarditis

Male 0301 basic medicine Cardiovascular Medical and Health Sciences Mice 03 medical and health sciences 2.1 Biological and endogenous factors Humans Animals Estrogen Receptor beta Myocytes, Cardiac Nerve Growth Factors Aetiology Immune Checkpoint Inhibitors Myocytes Estradiol Biological Sciences Estrogen 3. Good health [SDV] Life Sciences [q-bio] Myocarditis Heart Disease 5.1 Pharmaceuticals Female Development of treatments and therapeutic interventions Cardiac
DOI: 10.1126/scitranslmed.abo1981 Publication Date: 2022-11-02T17:58:46Z
ABSTRACT
Immune checkpoint inhibitors (ICIs) have been increasingly used in combination for cancer treatment but are associated with myocarditis. Here, we report that tumor-bearing mice exhibited response to combinatorial anti–programmed cell death 1 and anti–cytotoxic T lymphocyte antigen–4 antibodies also presented cardiovascular toxicities observed clinically ICI therapy, including myocarditis arrhythmia. Female were preferentially affected compared male mice, consistent a previously described genetic model of emerging clinical data. Mechanistically, myocardial tissue from ICI-treated the mouse model, human heart patients all down-regulation MANF (mesencephalic astrocyte–derived neurotrophic factor) HSPA5 (heat shock 70-kDa protein 5) heart; this was particularly notable female mice. amplified by heart-specific deletion Manf attenuated administration recombinant protein, suggesting causal role. Ironically, both transcriptionally induced liganded estrogen receptor β inhibited androgen receptor. However, reduced serum estradiol concentration greater extent Treatment an β–specific agonist depletion therapy ICI-associated cardiac effects. Together, our data suggest inhibits estradiol-dependent expression MANF/HSPA5 heart, curtailing cardiomyocyte immune injury. This endocrine-cardiac-immune pathway offers new insights into mechanisms sex differences disease may offer strategies
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (75)
CITATIONS (37)